Dec P
Dec P Uses, Dosage, Side Effects, Food Interaction and all others data.
Dec P is an anthelmintic drug that does not resemble other antiparasitic compounds. It is a synthetic organic compound which is highly specific for several parasites and does not contain any toxic metallic elements. Dec P continues to be the mainstay for treatment of patients with lymphatic filariasis and loiasis.
The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.
Dec P is an anthelmintic drug that does not resemble other antiparasitic compounds. It is a synthetic organic compound which is highly specific for several parasites and does not contain any toxic metallic elements.
| Trade Name | Dec P |
| Generic | Diethylcarbamazine |
| Diethylcarbamazine Other Names | Diethylcarbamazin, Diéthylcarbamazine, Diethylcarbamazine, Diethylcarbamazinum, Dietilcarbamazina |
| Type | Tablet |
| Formula | C10H21N3O |
| Weight | Average: 199.2932 Monoisotopic: 199.168462309 |
| Groups | Approved, Investigational, Vet approved |
| Therapeutic Class | Other Anti-protozoals |
| Manufacturer | Commonwealth Pharmaceuticals |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Dec P is used for Filariasis, Lymphatic filariasis, Pulmonary eosinophilia, Loiasis, Toxocariasis.
Dec P is also used to associated treatment for these conditions: Filarial Infection, Onchocerciasis
How Dec P works
The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.
Dosage
Dec P dosage
Inital: 1 mg/kg/day, may increase to 6 mg/kg/day over 3 days, then maintain for 3 wk. Prophylaxis of loiasis 300 mg/wk.
Side Effects
Fever, headache, vomiting, dizziness, drowsiness, nausea, chills.
Potentially Fatal: Severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare Mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. Encephalitis and retinal haemorrhage.
Toxicity
Oral LD50 in rat and mouse is 1400 mg/kg and 660 mg/kg, respectively.
Precaution
Patients with poor health.
Lactation: not known if excreted in breast milk.
Interaction
There are no known drug interactions and none well documented.
Elimination Route
Readily absorbed following oral administration.
Half Life
Approximately 8 hours.
Pregnancy & Breastfeeding use
Pregnancy Category- X. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Contraindication
Pregnancy, hypersensitivity; lactation; infants, elderly or debilitated patients; impaired renal function; cardiac disease.
Innovators Monograph
You find simplified version here Dec P
Dec P contains Diethylcarbamazine see full prescribing information from innovator Dec P Monograph, Dec P MSDS, Dec P FDA label
